Bez efektu

TU-100

• Contains established TRPA1 and TRPV1 channel activators, including
• (6)-shogaol and hydroxyl-beta-sanshool
• Proposed as a treatment for postoperative ileus, severe constipation, and symptoms of IBS and Crohn’s disease.
• TU-100 reverses opioid-induced constipation
• Enhances colonic contractions
• no evidence for TRP channel involvement in these effects
• Clinical trials have examined the therapeutic potential of TU-100 with limited success
• no significant effect on gastric emptying or on colonic motility
• Apparent inability to translate data from rodents to humans highlights potential limitations to this experimental approach.
• www.sciencedirect.com/topics/neuroscience/shogaol